1. Deze website gebruikt cookies. Door deze website verder te gebruiken, gaat u akkoord met ons gebruik van cookies. Leer Meer.

House Advances Broad Opioid Package; Senate Vote Next

Discussie in 'Nieuws en actualiteiten!' gestart door Twirley Bird, 1 nov 2018.

Azarius Smartshop headshop cannabis seeds
Azarius Smartshop headshop cannabis seeds
Azarius vaporizers and accessories
  1. Twirley Bird

    Twirley Bird Bewuste gebruiker

    Het is een rotzooi in Amerika met de zogenaamde 'Opiodes Crisis'

    Om daarover compleet op de hoogte te zijn hier wat niuews erover.
    Wel aantal kritische vragen waaronder de meest vreemde dat niemand heeft mogen stemmen welke opioden en opiaten er in dit 'package' zitten. Blijkbaar is de overheid een deel van het zorgsysteem aan het worden of zijn.

    Hier het artikel (in Engels Google Translate het als je het niet volgen kan)

    The US House of Representatives today approved a broad package of opioid legislation that's intended to give healthcare professionals and federal agencies new authority and new tasks for combating substance abuse.

    The Senate is expected to clear the package in the weeks ahead, as it represents a series of compromises negotiated between lawmakers in the two chambers. The White House has already signaled its strong support for this effort, making it likely that President Donald Trump will sign the package into law.

    The president today signed a separate spending bill into law that provides a historic level of funding — $6.6 billion — for efforts to treat and prevent substance abuse.

    There's broad bipartisan support to combat substance abuse, as reflected in the 393-8 House vote today on the opioid package. During the weeks of debate on this measure, many lawmakers noted the sharp increase in drug overdoses in recent years. The Centers for Disease Control and Prevention in August said the number of drug overdose deaths in the United States may have reached 72,000 last year, up from an estimated 66,000 in 2016 and 54,000 in 2015.

    "We have a lot more to do to address this opioid crisis, which is getting worse instead of better," Representative Frank Pallone Jr. (D-NJ), the ranking Democrat on the House Energy and Commerce Committee on the chamber's floor, said today. Still, Pallone and his GOP colleagues said they were pleased with the package they put up for a vote.

    "Seldom can we say that federal legislation will actually save lives, but we know this bipartisan package will do just that by improving treatment for those battling addiction and slowing the flow of illegal, deadly synthetic drugs into America," House Energy and Commerce Chairman Greg Walden (R-OR) said today.

    Running to about 660 pages in length, the opioid package sweeps in many proposals offered by members of both parties. Some of these expand the authority of federal agencies to try to stop abuse of prescription drugs and impede the flow of illegal narcotics into the United States. Many other provisions direct the Department of Health and Human Services (HHS) and other federal bodies to undertake further study of ways to combat substance abuse.

    The package, for example, would increase the number of healthcare providers who can prescribe or dispense medication-assisted treatment (MAT). It would authorize clinical nurse specialists, certified nurse midwives, and certified registered nurse anesthetists to prescribe MAT for 5 years, according to an Energy and Commerce summary of the bill.

    The measure also would allow waivered practitioners to immediately treat 100 patients at a time if a practitioner is board certified in addiction medicine or addiction psychiatry. The bill requires HHS, in consultation with the Drug Enforcement Administration, to give Congress a report that assesses the care provided by physicians treating more than 100 patients and nonphysician practitioners treating more than 30 patients, the committee said.

    Representative Michael C. Burgess, MD, (R-TX) chairman of the Energy and Commerce's health subcommittee, said he has concerns about the package's expansion of the ability of healthcare professionals other than physicians to prescribe. He said he hoped Congress would take another look at the issue.

    Burgess also expressed disappointment about a measure that was left out of the opioid package. The opioid measure "could have been stronger" if it included the text of a House bill about sharing substance abuse records, Burgess said. He's a supporter of a pending bill that would align rules about disclosure of past substance abuse more closely with the Health Insurance Portability and Accountability Act (HIPAA).

    Burgess and other advocates for the pending bill say it will reduce the chance of unknowingly prescribing an opioid to a person who has struggled in the past with addiction. Opponents of the measure, known as the Overdose Prevention and Patient Safety Act, contend it could open the door to discrimination against people who have abused drugs. Burgess said today that the bill had drawn strong bipartisan support when it was put on the House floor in June and predicts the debate isn't over.

    "That stand-alone bill received 357 votes in this House, and I promise you will see it again," Burgess said.

    Even with these flaws, though, the opioid package has Burgess' endorsement.

    "I cannot let the perfect be the enemy of the good," he said. "I urge our members to support this product today."

    The opioid package does include several provisions that direct HHS to study practices for prominently displaying substance use disorder treatment information in electronic health records, when patients request such sharing of information, according to the committee's summary.

    These provisions are known as Jessie's Law in honor of Jessica Grubb, a woman who was prescribed oxycodone pills after surgery. She'd earlier battled with addiction and overdosed on the postsurgery prescription.

    Other key provisions of the opioid measure that the House passed Friday include:

    Directing HHS to develop materials that clarify circumstances when pharmacists may decline to fill controlled substance prescriptions, such as when they suspect the prescriptions are fraudulent, forged, or of doubtful, questionable, or suspicious origin.

    Directing HHS, in consultation with the Justice Department, to submit to Congress a report on the impact of federal and state laws and regulations that limit the length, quantity, or dosage of opioid prescriptions.

    Expanding the types of professionals for whom makers of drug and medical devices must file reports with the Centers for Medicare and Medicaid Services' (CMS) Open Payments, or Sunshine Act, program. The companies would need to include physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives in these reports to CMS. The bill also sunsets the prohibition that prevents inclusion of the unique identification number, known as the National Provider Identifier, for all professionals and other entities displayed on the CMS Open Payments website, the committee said in its summary.

    No longer than 2 years after the date of enactment of the bill, HHS will be required to annually notify prescribers that they are identified as an outlier prescriber of opioids compared with other prescribers in their specialty and geographic area. HHS may exclude from this analysis cases of people in hospice or who have a cancer diagnosis, according to the committee summary.

    HHS will be required to review payments made through the Outpatient Prospective Payment System (OPPS) and payments to ambulatory surgery centers (ASCs) to ensure there are no financial incentives to use opioids instead of evidence-based nonopioid alternatives.

    Developing a program for 6-year loan repayment agreements for healthcare professionals specializing in substance abuse treatment in areas where there is a great need for these services.

    Expanding the use of telehealth services for the treatment of substance abuse by eliminating certain statutory originating site requirements for telehealth services furnished to people enrolled in Medicare for the treatment of substance use disorders and co-occurring mental health disorders beginning July 1, 2019. The committee summary said this provision would allow payment for those services furnished via telehealth at originating sites, including the home of a person covered by Medicare.

    The bill also includes a measure intended to close the loophole that lawmakers say has allowed foreign drug traffickers to ship drugs such as fentanyl into the United States. The provision is intended to hold the US Postal Service to the same screening standard as private mail carriers, requiring them to provide advance electronic data on international packages entering the United States, said Senator Rob Portman (R-OH), a sponsor of the provision, in a statement.

    "Perhaps once and for all we can do something about this poison coming into our country from eastern Asia to the detriment of our citizens," Burgess said on this provision, known as the STOP Act, on the House floor Friday.

    For more news, join us on Facebook and Twitter

    Bron : Medscape

    Verontrustend nieuws dit betekent dat de pijn patiënten er weer op achteruit gaan door recreatieve gebruikers die later als hun geen recept meer krijgen overstappen op heroine of fentanyl (analogen). Plus uit studie blijkt dat slechts 3% van de gebruikers verslaafd wordt. En de overige 97% het prima afbouwen en hebben ook geen cravings meer.

    Hopelijk worden ze daar op tijd wakker..
    Dit alles om 'slechts 517 patiënten per jaar die overdosis krijgen met prescription drugs' word miljarden voor uit getrokken. Dat krijg je ervan met zo'n figuur aan de top blijkt..
  2. acht.zes

    acht.zes Badass junkie De Leukste Thuis!

    Je doet nu net of de schuld bij de 'recreatieve' gebruikers ligt. En dat klopt dus niet. De schuld ligt bij de farmaceutische industrie en de overheid die een beleid hebben gehad van veel te zwaar spul in te zetten tegen zelfs lichte pijnklachten. En die patienten van toen zijn de verslaafden van nu oftwel wat jij 'recreatieve gebruikers' noemt.
    Jouw 3 % klopt ook voor geen meter, lijkt me een onderzoekje van de farmaceutische industrie te zijn die wordt ingezet om te lobbyen.

    Het gaat hier dezelfde kant uit. Ziekenhuizen worden tegenwoordig beoordeeld op hoeveel pijn hun patienten hebben (het befaamde pijnkaartje van 0 tot 10) en ook hier wordt tegenwoordig zware pijnstillers ingezet tegen milde pijnklachten. En daar moet dus iets aan gedaan worden, want dan zit je later niet met de gevolgen zoals in Amerika het geval is.
    Laatst bewerkt: 1 nov 2018
Azarius Smartshop headshop cannabis seeds
Azarius Smartshop headshop cannabis seeds
Azarius vaporizers and accessories